MindWalk (NASDAQ:HYFT) Rating Lowered to Sell at Wall Street Zen

MindWalk (NASDAQ:HYFT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research firms have also recently weighed in on HYFT. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. Finally, JonesTrading started coverage on MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, MindWalk presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Stock Performance

Shares of MindWalk stock opened at $1.36 on Friday. The company has a market capitalization of $63.53 million, a PE ratio of -6.18 and a beta of 0.83. The business’s 50-day moving average price is $1.56. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.80 and a quick ratio of 2.72. MindWalk has a 1-year low of $0.99 and a 1-year high of $3.25.

MindWalk (NASDAQ:HYFT) last posted its earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $3.03 million during the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. As a group, equities research analysts predict that MindWalk will post -0.21 EPS for the current year.

Hedge Funds Weigh In On MindWalk

Several hedge funds have recently added to or reduced their stakes in HYFT. Renaissance Technologies LLC boosted its stake in shares of MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares during the last quarter. Bank of Montreal Can increased its holdings in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of MindWalk during the 4th quarter worth about $51,000. XTX Topco Ltd increased its position in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after buying an additional 44,331 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in shares of MindWalk during the 4th quarter worth approximately $91,000. Institutional investors own 6.70% of the company’s stock.

Key Headlines Impacting MindWalk

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on MindWalk and the broader brokerage view remains Moderate Buy, suggesting Wall Street still sees upside potential despite near-term losses. MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: MindWalk’s latest earnings call highlighted the company’s growth efforts, but the business is still posting persistent losses, keeping investor focus on the path to profitability. MindWalk Holdings Charts Growth Amid Persistent Losses
• Negative Sentiment: HC Wainwright cut earnings estimates across multiple periods, including FY2027, FY2028, FY2029, and FY2030, signaling a weaker profit outlook and pressuring the stock. Brokers Issue Forecasts for MindWalk FY2031 Earnings
• Negative Sentiment: Another analyst report from Wall Street Zen lowered its rating on HYFT, adding to concerns that recent expectations may be too optimistic. MindWalk (NASDAQ:HYFT) Stock Rating Lowered by Wall Street Zen

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.